Nektar Therapeutics (NKTR): What's the Story?

Analyst Nektar Has A Handful Of Milestones Ahead In 2018

Nektar Therapeutics on 9/29/2017 reported its EPS as $-0.28 with the analysts projecting the EPS of the stock as $-0.26. Stoneridge Ltd Liability Company has invested 0.15% in Nektar Therapeutics (NASDAQ:NKTR). They issued a "buy" rating and a $30.00 target price for the company.

Other equities research analysts have also issued research reports about the stock. BidaskClub lowered shares of Nektar Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, August 11th. Evercore initiated the shares of NKTR in report on Thursday, August 17 with "In-Line" rating. Credit Suisse Ag reported 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Mizuho reissued a "buy" rating and issued a $30.00 target price on shares of Nektar Therapeutics in a report on Wednesday.

Among 11 analysts covering Vonage (NYSE:VG), 9 have Buy rating, 0 Sell and 2 Hold. The timing of purchasing a researched stock obviously comes with some level of trepidation.

More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Streetinsider.com and their article: "Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) Report First Data ..." published on November 13, 2017 as well as Seekingalpha.com's news article titled: "Nektar Therapeutics: Updates To Thesis" with publication date: November 08, 2017. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and global copyright laws. Nektar Therapeutics has recorded a 50-day average of $23.01 and a two hundred day average of $20.46.

TRADEMARK VIOLATION WARNING: "Nektar Therapeutics (NKTR) PT Raised to $44.00 at J P Morgan Chase & Co" was originally reported by TrueBlueTribune and is owned by of TrueBlueTribune. Nektar Therapeutics has a 1 year low of $11.41 and a 1 year high of $33.67. The company has a debt-to-equity ratio of 2.91, a quick ratio of 3.82 and a current ratio of 4.14.


Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Tuesday, November 7th. Cowen and Company began coverage on shares of Nektar Therapeutics in a research report on Tuesday, November 7th. Nektar Therapeutics had a negative return on equity of 8,769.15% and a negative net margin of 98.87%. The business had revenue of $152.90 million during the quarter, compared to analyst estimates of $126.50 million. Over the past month the firm's stock is 41.18%, 68.57% for the last quarter, 64.06% for the past six-months and 137.57% for the a year ago. The company's price to sales ratio for trailing twelve months is 13.51 and price to book ratio for most recent quarter is 2.27, whereas price to cash per share for the most recent quarter is 62.20.

In other news, SVP Stephen K. Doberstein sold 1,701 shares of Nektar Therapeutics stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $19.32, for a total value of $51,159.36. The transaction was disclosed in a filing with the SEC, which is available at this link. The investor checklist may include studying the scope of a company's competitive industry advantage, examining company management, and trying to get a general feel if the stock is valued properly. While the stock price moved along with the volume change, shares are touching $0.52. Following the sale, the senior vice president now directly owns 31,102 shares in the company, valued at approximately $600,890.64. The disclosure for this purchase can be found here. The stock has added 13% since pricing its initial public offering (IPO) of $24 per share on October 18, the fourth-largest U.S. IPO this year. Insiders own 5.44% of the company's stock.

Large investors have recently added to or reduced their stakes in the business. State of Wisconsin Investment Board bought a new stake in Nektar Therapeutics in the 2nd quarter valued at about $2,248,000. After $0.60 actual earnings per share reported by Plantronics Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth. The value of the company's investment in Nektar Therapeutics went from $2,187,000 to $2,841,000 a change of $654,000 since the last quarter. Legal & General Group Plc lifted its position in shares of Nektar Therapeutics by 3.9% during the 3rd quarter. Short shares decreased from 12,723,557 to 12,559,722 over that period.

Robertson Opportunity Capital Llc holds 3.21% of its portfolio in Cypress Semiconductor Corporation for 370,000 shares.

Nektar Therapeutics is a biopharmaceutical firm that discovers and develops medicines in areas of high unmet medical need.

Related:

Comments

Latest news

London’s Medical Startups Challenge Welcomes a New Judge, Max Polyakov
MBios is a joint project of Innovation House and the Ukrainian Medical Association of the United Kingdom (UMAUK). Such kind of challenges provides the participants with an opportunity to present their projects to the world.

Ben Affleck Still 'Contemplating' Matt Reeves' Batman Film
The question of Affleck's long-term involvement certainly isn't something new. Affleck could simply be in a holding pattern for a couple of reasons.

Trump Asked Xi To Resolve UCLA Basketball Player Case
White House press secretary Sarah Sanders confirmed in an email that Trump raised the matter with Xi, The Post reported. However, the charges against the players were reduced and the case was headed toward a resolution, a source told ESPN.

Hijab-Wearing Barbie Makes Her Debut
It's a massive step forward for the iconic doll, and a moment that matters for Muslim women and girls everywhere. By being a badass Muslim fencer, Muhammad is a ideal candidate and honoree to help move this campaign forward.

Celebrities Who Suffer With Chronic Diseases
Now if that isn’t the epitome of what a BFF is, I don’t know what is! Selena continues to be on chronic medication. There is also a huge list of celebrities past like famous painter vincent Van Gogh who suffered with this disease.

Other news